HOME   |   ABOUT   |   CONTACT

Cannabidiol (CBD) for clozapine refractory schizophrenia (CanCloz)

Cannabidiol (CBD) for clozapine refractory schizophrenia (CanCloz)

Treatment refractory schizophrenia (TRS) is a debilitating disorder that affects one in three adults with schizophrenia. Clozapine is the only antipsychotic licenced for TRS and can transform these people’s lives. However, only 40% of patients achieve an adequate response. There is an urgent need for novel, safe and effective clozapine augmentation agents.

Cannabidiol, a psychoactive derivative of cannabis, has shown promise as a safe treatment for people with schizophrenia. To date, however, it has not been trialled in people with clozapine refractory schizophrenia.

The CanCloz trial is an investigator-initiated multi-centre double-blind randomised placebo-controlled pilot trial to assess the safety and tolerability of CBD for psychotic symptoms among people with schizophrenia refractive to clozapine.

Funding
PA Research Foundation

Investigators

  • Prof Dan Siskind (Lead Investigator)
  • Ms Andrea Baker – clinical trials coordinator
  • Associate Professor Nicola Warren – neuropsychiatrist
  • Prof Iain McGregor, The Lambert Initiative for Cannabinoid Therapeutics, School of Psychology, University of Sydney

Study site
Princess Alexandra Hospital Southside Clinical Unit

Image

HEAD OFFICE

Level 3, Dawson House
The Park Centre for Mental Health Treatment
Research and Education, Wacol, QLD 4076
P: +61 7 3271 8660

ACKNOWLEDGEMENT OF COUNTRY

In the spirit of reconciliation, the Queensland Centre for Mental Health Research (QCMHR) acknowledges the Traditional Owners of the lands in which QCMHR operates and their continuing connections to land, waters and community. We pay our respects to Elders past and present and stand together with all Aboriginal and Torres Strait Islander peoples.